Vera Therapeutics (VERA) Stock Overview
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VERA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.00 |
| 52 Week High | US$51.61 |
| 52 Week Low | US$18.53 |
| Beta | 1.13 |
| 1 Month Change | 25.32% |
| 3 Month Change | 9.20% |
| 1 Year Change | -22.30% |
| 3 Year Change | 133.54% |
| 5 Year Change | n/a |
| Change since IPO | 178.22% |
Recent News & Updates
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)
Jun 04Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
Mar 14
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?
Mar 07Recent updates
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)
Jun 04Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
Mar 14Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?
Mar 07Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late
Dec 22Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?
Oct 07Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Oct 04Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy
Jul 22Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?
Jul 05Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Jan 25Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Sep 06Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Aug 10Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Feb 16Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Jan 19Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Jan 07We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Oct 25Shareholder Returns
| VERA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 69.6% | 1.7% | 0.7% |
| 1Y | -22.3% | -10.7% | 12.6% |
Return vs Industry: VERA underperformed the US Biotechs industry which returned -10.7% over the past year.
Return vs Market: VERA underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| VERA volatility | |
|---|---|
| VERA Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VERA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VERA's weekly volatility has increased from 13% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 152 | Marshall Fordyce | veratx.com |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases.
Vera Therapeutics, Inc. Fundamentals Summary
| VERA fundamental statistics | |
|---|---|
| Market cap | US$1.97b |
| Earnings (TTM) | -US$175.46m |
| Revenue (TTM) | n/a |
Is VERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$175.46m |
| Earnings | -US$175.46m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 9.5% |
How did VERA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 22:51 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vera Therapeutics, Inc. is covered by 15 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Liisa Bayko | Evercore ISI |
| Paul Choi | Goldman Sachs |